CompletedNot Applicable

Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0)

France60 participantsStarted 2014-09

Plain-language summary

Prospective, open labelled, monocentric trial to evaluation of the circulating tumor DNA rate in the blood, before and after curative resection of hepatic metastasis of uveal melanoma (HMUM) and during post-surgery follow-up

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Aged 18 years old or more
✓. Patient with hepatic injury of metastatic uveal melanoma eligible for curative surgery (R0).
✓. No other distant metastasis (CT thoracic -abdomino -pelvic, bone scan).Measurable metastatic disease (echography, CT and/or MRI, FDG-PET, (fluoro- D-glucose integrated with computed tomography)).
✓. Patient able to stand a blood collection.
✓. Patient explanation given and consent information signed or by legal representative.

Exclusion criteria

✕. Patient without social protection / insurance..
✕. Patient with hepatic metastasis unresectable by surgery
✕. Patient with extra-hepatic metastasis.
✕. Person deprived of liberty or under guardianship
✕0. Inability to submit to medical monitoring of the trial for reasons of geography, social or psychological.

What they're measuring

Correlation between the circulating tumor DNA rate before/after surgery and the rate of effective complete resection

Timeframe: Up to one month

Trial details

NCT IDNCT02849145

SponsorInstitut Curie

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-02-25

View on ClinicalTrials.gov More Uveal Melanoma trials